To the best of our knowledge, no comprehensive investigation has yet assessed its therapeutic potential in in vivo breast cancer models, particularly regarding its influence on proliferation-associated markers (e.g., PCNA), inflammatory cytokines (e.g., TNF-α), and its immunomodulatory interactions with tumor immune subtypes and cellular infiltration in the tumor microenvironment (TME). Here, PCNA is linked to breast carcinoma.